Cannabis Biotech, a subsidiary of Puget Technologies, is introducing product research for a transmucosal delivery system to deliver medical marijuana through the mucous membrane of the nasal cavity.
Cannabis Biotech's new project is targeted towards those who desire the benefits of medical marijuana but do not want the harmful effects or stigma of smoking it.
Patients have been well accepting the uptake of medicine via transmucosal systems.
GlaxoSmithKline's Flonase (fluticasone propionate), AstraZeneca's Rhinocort Aqua (budesonide), and Novartis' Ortrivine adult metered dose are popular medications that are commonly used by the patients in the US to treat hay fever and other allergies.
This methodology is used as an anti-influenza therapy and to treat Vitamin B deficiency, osteoporosis and nicotine addiction among other conditions.
Puget Technologies president and CEO Ron Leyland noted modern medicine derived from cannabis is coming out of the shadows and a more varied group of patients are expected to seek out its benefits.
"Cannabis Biotech is poised to deliver scientifically engineered products to meet their needs. The multi-billion dollar medical marijuana industry offers excellent growth prospects for Cannabis Biotech which is committed to maintaining strict protocols and quality standards," Leyland added.
Cannabis BioTech has signed a consulting agreement with Kenneth Morrow, a medical marijuana consultant, in October 2013 to round out the company's research and development team.
"Morrow noted this platform will allow for an enhanced therapeutic effect while providing patients with an accurate dosing regimen and a steady rate of delivery across the mucous membrane, avoiding the gastrointestinal tract and loss of a percentage of the medicine through the liver.
"This product had the potential to replace current similar products in the market which are much less standardized and regulated," Morrow added.